Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, 405 30 Gothenburg, Sweden.
Region Västra Götaland, Department of Acute Medicine and Geriatrics, Sahlgrenska University Hospital, 413 45 Gothenburg, Sweden.
Int J Mol Sci. 2024 Apr 30;25(9):4931. doi: 10.3390/ijms25094931.
Both high serum insulin-like growth factor-binding protein-1 (s-IGFBP-1) and insulin resistance (IR) are associated with poor functional outcome poststroke, whereas overweight body mass index (BMI; 25-30) is related to fewer deaths and favorable functional outcome in a phenomenon labeled "the obesity paradox". Furthermore, IGFBP-1 is inversely related to BMI, in contrast to the linear relation between IR and BMI. Here, we investigated s-IGFBP-1 and IR concerning BMI and 7-year poststroke functional outcome. We included 451 stroke patients from the Sahlgrenska Study on Ischemic Stroke (SAHLSIS) with baseline measurements of s-IGFBP1, homeostasis model assessment of IR (HOMA-IR), BMI (categories: normal-weight (8.5-25), overweight (25-30), and obesity (>30)), and high-sensitivity C-reactive protein (hs-CRP) as a measure of general inflammation. Associations with poor functional outcome (modified Rankin scale [mRS] score: 3-6) after 7 years were evaluated using multivariable binary logistic regression, with overweight as reference due to the nonlinear relationship. Both normal-weight (odds-ratio [OR] 2.32, 95% confidence interval [CI] 1.30-4.14) and obese (OR 2.25, 95% CI 1.08-4.71) patients had an increased risk of poor functional outcome, driven by deaths only in the normal-weight. In normal-weight, s-IGFBP-1 modestly attenuated (8.3%) this association. In the obese, the association was instead attenuated by HOMA-IR (22.4%) and hs-CRP (10.4%). Thus, a nonlinear relation between BMI and poor 7-year functional outcome was differently attenuated in the normal-weight and the obese.
高血清胰岛素样生长因子结合蛋白-1 (s-IGFBP-1) 和胰岛素抵抗 (IR) 均与卒中后功能预后不良相关,而超重的体重指数 (BMI; 25-30) 与较少的死亡和有利的功能预后相关,这种现象被称为“肥胖悖论”。此外,IGFBP-1 与 BMI 呈负相关,而 IR 与 BMI 呈线性关系。在这里,我们研究了 s-IGFBP-1 和 IR 与 BMI 以及卒中后 7 年的功能预后的关系。我们纳入了 Sahlgrenska 缺血性卒中研究 (SAHLSIS) 的 451 名卒中患者,基线时测量了 s-IGFBP1、稳态模型评估的 IR (HOMA-IR)、BMI(分类:正常体重 (8.5-25)、超重 (25-30) 和肥胖 (>30))和高敏 C 反应蛋白 (hs-CRP),作为全身炎症的指标。使用多变量二项逻辑回归评估了 7 年后功能预后不良(改良 Rankin 量表[mRS]评分:3-6)的相关性,由于存在非线性关系,超重为参考。正常体重(比值比 [OR] 2.32,95%置信区间 [CI] 1.30-4.14)和肥胖(OR 2.25,95% CI 1.08-4.71)患者的功能预后不良风险均增加,这主要是由于正常体重患者的死亡所致。在正常体重患者中,s-IGFBP-1 轻度减弱了这种相关性(8.3%)。在肥胖患者中,HOMA-IR(22.4%)和 hs-CRP(10.4%)减弱了这种相关性。因此,BMI 与 7 年功能预后不良之间的非线性关系在正常体重和肥胖患者中表现出不同的减弱。